Immunotherapy for melanoma

Lamberg, 2002, “Epidemic” of malignant melanoma, JAMA, 287, 2201, 10.1001/jama.287.17.2201 Nestle, 1999, New perspectives on immunobiology and immunotherapy of melanoma, Immunol Today, 20, 5, 10.1016/S0167-5699(98)01373-5 Horig, 1999, Current issues in cancer vaccine development, Clin Immunol, 92, 211, 10.1006/clim.1999.4751 De Plaen, 1988, Immunogenic (tum-) variants of mouse tumor P815, Proc Natl Acad Sci USA, 85, 2274, 10.1073/pnas.85.7.2274 van der Bruggen, 1991, A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma, Science, 254, 1643, 10.1126/science.1840703 Romero, 2002, Antigenicity and immunogenicity of Melan-A/MART-1 derived peptides as targets for tumor reactive CTL in human melanoma, Immunol Rev, 188, 81, 10.1034/j.1600-065X.2002.18808.x Chen, 1997, A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening, Proc Natl Acad Sci USA, 194, 1914, 10.1073/pnas.94.5.1914 Jager, 1998, Simultaneous humoral and cellular immune response against cancer-testis antigen NY-ESO-1, J Exp Med, 187, 265, 10.1084/jem.187.2.265 Zeng, 2002, Generation of NY-ESO-1-specific CD4+ and CD8+ T cells by a single peptide with dual MHC class I and class II specificities, Cancer Res, 62, 3630 Jager, 1999, Humoral immune responses of cancer patients against “Cancer-Testis” antigen NY-ESO-1, Int J Cancer, 84, 506, 10.1002/(SICI)1097-0215(19991022)84:5<506::AID-IJC10>3.0.CO;2-6 Zeng, 2001, MHC Class II-restricted tumor antigens recognized by CD4+ T cells, J Immunother, 24, 195, 10.1097/00002371-200105000-00002 Consogno, 2003, Identification of immunodominant regions among promiscuous HLA-DR-restricted CD4+ T-cell epitopes on the tumor antigen MAGE-3, Blood, 101, 1038, 10.1182/blood-2002-03-0933 Robbins, 2002, Multiple HLA class II-restricted melanocyte differentiation antigens are recognized by tumor-infiltrating lymphocytes from a patient with melanoma, J Immunol, 169, 6036, 10.4049/jimmunol.169.10.6036 Novellino, 2003, Identification of a mutated receptor-like protein tyrosine phosphatase kappa as a novel, class II HLA-restricted melanoma antigen, J Immunol, 170, 6363, 10.4049/jimmunol.170.12.6363 Zeng, 2002, Generation of NY-ESO-1-specific CD4+ and CD8+ T cells by a single peptide with dual MHC class I and class II specificities, Cancer Res, 62, 3630 Dunn, 2002, Cancer immunoediting, Nat Immunol, 3, 991, 10.1038/ni1102-991 Darrow, 1989, The role of HLA class I antigens in recognition of melanoma cells by tumor-specific cytotoxic T lymphocytes. Evidence for shared tumor antigens, J Immunol, 142, 3329, 10.4049/jimmunol.142.9.3329 de Vries, 1997, Heterogeneous expression of immunotherapy candidate proteins gp100, MART-1, and tyrosinase in human melanoma cell lines and in human melanocytic lesions, Cancer Res, 57, 3223 Garcia-Lora, 2003, MHC class I antigens, immune surveillance, and tumor immune escape, J Cell Physiol, 195, 346, 10.1002/jcp.10290 Wang, 1993, Lack of HLA class I antigen expression by melanoma cells SK-MEL-33 caused by a reading frameshift in beta 2-microglobulin messenger RNA, J Clin Invest, 91, 684, 10.1172/JCI116249 Restifo, 1996, Loss of functional beta 2-microglobulin in metastatic melanomas from five patients receiving immunotherapy, J Natl Cancer Inst, 88, 100, 10.1093/jnci/88.2.100 Ferrone, 1995, Loss of HLA class I antigens by melanoma cells, Immunol Today, 16, 487, 10.1016/0167-5699(95)80033-6 Ruiter, 1991, MHC antigens in human melanomas, Semin Cancer Biol, 2, 35 Ikeda, 1997, Characterization of an antigen that is recognized on a melanoma showing partial HLA loss by CTL expressing an NK inhibitory receptor, Immunity, 6, 199, 10.1016/S1074-7613(00)80426-4 Khong, 2002, Natural selection of tumor variants in the generation of “tumor escape” phenotypes, Nat Immunol, 3, 999, 10.1038/ni1102-999 Gerosa, 2002, Reciprocal activating interaction between natural killer cells and dendritic cells, J Exp Med, 195, 327, 10.1084/jem.20010938 Galea-Lauri, 1999, Expression of a variant of CD28 on a subpopulation of human NK cells, J Immunol, 163, 62, 10.4049/jimmunol.163.1.62 Takeda, 2000, CD27-mediated activation of murine NK cells, J Immunol, 164, 1741, 10.4049/jimmunol.164.4.1741 Staveley-O'Carroll, 1998, Induction of antigen-specific T cell anergy, Proc Natl Acad Sci USA, 95, 1178, 10.1073/pnas.95.3.1178 Slingluff, 1999, Targeting unique tumor antigens and modulating the cytokine environment may improve immunotherapy for tumors with immune escape mechanisms, Cancer Immunol Immunother, 48, 371, 10.1007/s002620050588 Goto, 1999, Analysis of Th1 and Th2 cytokine production by peripheral blood mononuclear cells as a parameter of immunological dysfunction in advanced cancer patients, Cancer Immunol Immunother, 48, 435, 10.1007/s002620050620 Keilholz, 2002, Immunologic monitoring of cancer vaccine therapy, J Immunother, 25, 97, 10.1097/00002371-200203000-00001 Inge, 1992, Inhibition of tumor-specific cytotoxic T-lymphocyte responses by transforming growth factor beta 1, Cancer Res, 52, 1386 von Rohr, 1992, Clinical applications of interleukin-2, Prog Growth Factor Res, 4, 229, 10.1016/0955-2235(92)90021-9 Holland, 1993, Interleukin-10 and cancer, Cancer Invest, 11, 751, 10.3109/07357909309046950 Mocellin, 2003, The dual role of IL-10, Trends Immunol, 24, 36, 10.1016/S1471-4906(02)00009-1 Letterio, 1998, TGF-beta knockout and dominant-negative receptor transgenic mice, Miner Electrolyte Metab, 24, 161, 10.1159/000057365 Singh, 2000, IL-8 expression in malignant melanoma, Histol Histopathol, 15, 843 Lazar-Molnar, 2000, Autocrine and paracrine regulation by cytokines and growth factors in melanoma, Cytokine, 12, 547, 10.1006/cyto.1999.0614 Milton, 1971, Malignant melanoma and vitiligo, Australas J Dermatol, 12, 131, 10.1111/j.1440-0960.1971.tb00001.x Berd, 1996, Melanoma and vitiligo, Cancer Immunol Immunother, 42, 263, 10.1007/s002620050280 Le Gal, 2001, Direct evidence to support the role of antigen-specific CD8(+) T cells in melanoma-associated vitiligo, J Invest Dermatol, 117, 1464, 10.1046/j.0022-202x.2001.01605.x Rosenberg, 1985, Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer, N Engl J Med, 313, 1485, 10.1056/NEJM198512053132327 Yee, 2000, Melanocyte destruction after antigen-specific immunotherapy of melanoma, J Exp Med, 192, 1637, 10.1084/jem.192.11.1637 Palermo, 2001, Specific cytotoxic T lymphocyte responses against Melan-A/MART1, tyrosinase and gp100 in vitiligo by the use of major histocompatibility complex/peptide tetramers, J Invest Dermatol, 117, 326, 10.1046/j.1523-1747.2001.01408.x Nordlund, 1983, Vitiligo in patients with metastatic melanoma, J Am Acad Dermatol, 9, 689, 10.1016/S0190-9622(83)70182-9 Rosenberg, 1996, Vitiligo in patients with melanoma, J Immunother Emphasis Tumor Immunol, 19, 81, 10.1097/00002371-199601000-00009 Halliday, 1995, Spontaneous regression of human melanoma/nonmelanoma skin cancer, World J Surg, 19, 352, 10.1007/BF00299157 Sondergaard, 1985, Partial regression in thin primary cutaneous malignant melanomas clinical stage I. A study of 486 cases, Virchows Arch A Pathol Anat Histopathol, 408, 241, 10.1007/BF00707986 Fearfield, 2001, Clinico-pathological features of relapsing very thin melanoma, Clin Exp Dermatol, 26, 686, 10.1046/j.1365-2230.2001.00920.x Weiner, 2000, New approaches to antibody therapy, Oncogene, 19, 6144, 10.1038/sj.onc.1204000 Houghton, 2000, Monoclonal antibody therapies—a “constant” threat to cancer, Nat Med, 6, 373, 10.1038/74621 Hodi, 2003, Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients, Proc Natl Acad Sci USA, 100, 4712, 10.1073/pnas.0830997100 Rafiq, 2002, Immune complex-mediated antigen presentation induces tumor immunity, J Clin Invest, 110, 71, 10.1172/JCI0215640 Clynes, 2000, Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets, Nature Med, 6, 443, 10.1038/74704 Foon, 2000, Clinical and immune responses in advanced melanoma patients immunized with an anti-idiotype antibody mimicking disialoganglioside GD2, J Clin Oncol, 18, 376, 10.1200/JCO.2000.18.2.376 Rosenberg, 1985, Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer, N Engl J Med, 313, 1485, 10.1056/NEJM198512053132327 Rosenberg, 1998, Durability of complete responses in patients with metastatic cancer treated with high-dose interleukin-2, Ann Surg, 228, 307, 10.1097/00000658-199809000-00004 Atkins, 2000, High-dose recombinant interleukin-2 therapy in patients with metastatic melanoma, Cancer J Sci Am, 6, S11 Ridolfi, 2002, Cisplatin, dacarbazine with or without subcutaneous interleukin-2, and interferon alpha-2b in advanced melanoma outpatients, J Clin Oncol, 20, 1600, 10.1200/JCO.20.6.1600 Atkins, 2002, A phase II pilot trial of concurrent biochemotherapy with cisplatin, vinblastine, temozolomide, interleukin 2, and IFN-alpha 2B in patients with metastatic melanoma, Clin Cancer Res, 8, 3075 Royal, 1996, Correlates of response to IL-2 therapy in patients treated for metastatic renal cancer and melanoma, Cancer J Sci Am, 6, 91 Phan, 2001, Factors associated with response to high-dose interleukin-2 in patients with metastatic melanoma, J Clin Oncol, 19, 3477, 10.1200/JCO.2001.19.15.3477 West, 1987, Constant-infusion recombinant interleukin-2 in adoptive immunotherapy of advanced cancer, N Engl J Med, 316, 898, 10.1056/NEJM198704093161502 Thurber, 2002, Identification of endogenous HLA-A2-restricted reactivity against shared melanoma antigens in patients using the quantitative real-time polymerase chain reaction, J Immunother, 25, 63, 10.1097/00002371-200201000-00007 Panelli, 2002, Gene-expression profiling of the response of peripheral blood mononuclear cells and melanoma metastases to systemic IL-2 administration, Genome Biol, 3, 1, 10.1186/gb-2002-3-7-research0035 Kammula, 1998, Trends in the safety of high dose bolus interleukin-2 administration in patients with metastatic cancer, Cancer, 83, 797, 10.1002/(SICI)1097-0142(19980815)83:4<797::AID-CNCR25>3.0.CO;2-M Schwartzentruber, 2001, Guidelines for the safe administration of high-dose interleukin-2, J Immunother, 24, 287, 10.1097/00002371-200107000-00004 Kirkwood, 1995, Melanoma, 388 Cole, 1996, Quality-of-life-adjusted survival analysis of interferon alfa-2b adjuvant treatment of high-risk resected cutaneous melanoma, J Clin Oncol, 14, 2666, 10.1200/JCO.1996.14.10.2666 Kirkwood, 1996, Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma, J Clin Oncol, 14, 7, 10.1200/JCO.1996.14.1.7 Kirkwood, 2000, High- and low-dose interferon alfa-2b in high-risk melanoma, J Clin Oncol, 18, 2444, 10.1200/JCO.2000.18.12.2444 Cascinelli, 2001, Effect of long-term adjuvant therapy with interferon alpha-2a in patients with regional node metastases from cutaneous melanoma, Lancet, 358, 866, 10.1016/S0140-6736(01)06068-8 Kirkwood, 2001, Pooled analysis of four ECOG-Intergroup trials of high-dose interferon alfa-2b (HDI) in 1916 patients with high-risk resected cutaneous melanoma, Proc ASCO, 20, 1395 Kirkwood, 2001, High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma, J Clin Oncol, 19, 2370, 10.1200/JCO.2001.19.9.2370 Eggermont, 2001, The European Organization for research and Treatment of Cancer Melanoma Group Trial Experience with more than 2000 patients, evaluating adjuvant therapy treatment with low or intermediate doses of interferon Alpha-2b, 88 Grabstein, 1986, Induction of macrophage tumoricidal activity by granulocyte-macrophage colony-stimulating factor, Science, 232, 506, 10.1126/science.3083507 Haddad, 2000, Plasmid vaccine expressing granulocyte-macrophage colony-stimulating factor attracts infiltrates including immature dendritic cells into injected muscles, J Immunol, 165, 3772, 10.4049/jimmunol.165.7.3772 Kass, 2001, Granulocyte/macrophage-colony stimulating factor produced by recombinant avian poxviruses enriches the regional lymph nodes with antigen-presenting cells and acts as an immunoadjuvant, Cancer Res, 61, 206 Kusumoto, 2001, Phase 1 clinical trial of irradiated autologous melanoma cells adenovirally transduced with human GM-CSF gene, Cancer Immunol Immunother, 50, 373, 10.1007/s002620100213 Spitler, 2000, Adjuvant therapy of stage III and IV malignant melanoma using granulocyte-macrophage colony-stimulating factor, J Clin Oncol, 18, 1614, 10.1200/JCO.2000.18.8.1614 Trinchieri, 1995, Interleukin-12, Annu Rev Immunol, 13, 251, 10.1146/annurev.iy.13.040195.001343 Fallarino, 1996, Endogenous IL-12 is necessary for rejection of P815 tumor variants in vivo, J Immunol, 156, 1095, 10.4049/jimmunol.156.3.1095 Diefenbach, 1999, Requirement for type 2 NO synthase for IL-12 signaling in innate immunity, Science, 284, 951, 10.1126/science.284.5416.951 Mortarini, 2000, Peripheral burst of tumor-specific cytotoxic T lymphocytes and infiltration of metastatic lesions by memory CD8+ T cells in melanoma patients receiving interleukin 12, Cancer Res, 60, 3559 Wang, 2001, Vaccination with IL-18 gene-modified, superantigen-coated tumor cells elicits potent antitumor immune response, J Cancer Res Clin Oncol, 127, 718, 10.1007/s004320100291 Yajima, 2002, Overexpression of interleukin-15 in vivo enhances antitumor activity against MHC class I-negative and -positive malignant melanoma through augmented NK activity and cytotoxic T-cell response, Int J Cancer, 99, 573, 10.1002/ijc.10395 Brombacher, 2003, Novel IL-12 family members shed light on the orchestration of Th1 responses, Trends Immunol, 24, 207, 10.1016/S1471-4906(03)00067-X Wang, 2001, Vaccination with IL-18 gene-modified, superantigen-coated tumor cells elicits potent antitumor immune response, J Cancer Res Clin Oncol, 127, 718, 10.1007/s004320100291 Player, 1996, Differences in frequency distribution of HLA-A2 subtypes between North American and Italian white melanoma patients, J Immunother Emphasis Tumor Immunol, 19, 357, 10.1097/00002371-199609000-00005 Rosenberg, 1998, Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma, Nat Med, 4, 321, 10.1038/nm0398-321 Romero, 2002, Antigenicity and immunogenicity of Melan-A/MART-1 derived peptides as targets for tumor reactive CTL in human melanoma, Immunol Rev, 188, 81, 10.1034/j.1600-065X.2002.18808.x Blachere, 1995, Heat shock protein-based cancer vaccines and related thoughts on immunogenicity of human tumors, Semin Cancer Biol, 6, 349, 10.1016/1044-579X(95)90004-7 Janetzki, 2000, Immunization of cancer patients with autologous cancer-derived heat shock protein gp96 preparations, Int J Cancer, 88, 232, 10.1002/1097-0215(20001015)88:2<232::AID-IJC14>3.0.CO;2-8 Belli, 2002, Vaccination of metastatic melanoma patients with autologous tumor-derived heat shock protein gp96-peptide complexes, J Clin Oncol, 20, 4169, 10.1200/JCO.2002.09.134 Castelli, 2001, Human heat shock protein 70 peptide complexes specifically activate antimelanoma T cells, Cancer Res, 61, 222 Andre, 2002, Malignant effusions and immunogenic tumour-derived exosomes, Lancet, 360, 295, 10.1016/S0140-6736(02)09552-1 Wallack, 1983, A preliminary trial of vaccinia oncolysates in the treatment of recurrent melanoma with serologic responses to the treatment, J Biol Response Mod, 2, 586 Hersey, 1987, Evidence that treatment with vaccinia melanoma cell lysates (VMCL) may improve survival of patients with stage II melanoma. Treatment of stage II melanoma with viral lysates, Cancer Immunol Immunother, 25, 257, 10.1007/BF00199156 Hersey, 2002, Adjuvant immunotherapy of patients with high-risk melanoma using vaccinia viral lysates of melanoma, J Clin Oncol, 20, 4181, 10.1200/JCO.2002.12.094 Rosenberg, 1998, Immunizing patients with metastatic melanoma using recombinant adenoviruses encoding MART-1 or gp100 melanoma antigens, J Natl Cancer Inst, 90, 1894, 10.1093/jnci/90.24.1894 Wallack, 1986, A Southeastern Cancer Study Group phase I/II trial with vaccinia melanoma oncolysates, Cancer, 57, 649, 10.1002/1097-0142(19860201)57:3<649::AID-CNCR2820570342>3.0.CO;2-6 Wallack, 1987, Positive relationship of clinical and serologic responses to vaccinia melanoma oncolysate, Arch Surg, 122, 1460, 10.1001/archsurg.1987.01400240108020 Irvine, 1997, Enhancing efficacy of recombinant anticancer vaccines with prime/boost regimens that use two different vectors, J Natl Cancer Inst, 89, 1595, 10.1093/jnci/89.21.1595 Hodge, 1997, Diversified prime and boost protocols using recombinant vaccinia virus and recombinant non-replicating avian pox virus to enhance T-cell immunity and antitumor responses, Vaccine, 15, 759, 10.1016/S0264-410X(96)00238-1 Townsend, 1993, Tumor rejection after direct costimulation of CD8+ T cells by B7-transfected melanoma cells, Science, 259, 368, 10.1126/science.7678351 Hodge, 1995, Admixture of a recombinant vaccinia virus containing the gene for the costimulatory molecule B7 and a recombinant vaccinia virus containing a tumor-associated antigen gene results in enhanced specific T-cell responses and antitumor immunity, Cancer Res, 55, 3598 Kaufman, 2000, A phase I trial of intra lesional RV-B7.1 vaccine in the treatment of malignant melanoma, Hum Gene Ther, 11, 1065, 10.1089/10430340050015374 Liang, 2002, The right place at the right time, Curr Opin Immunol, 14, 384, 10.1016/S0952-7915(02)00342-4 Dubey, 1995, Costimulatory requirements of naive CD4+ T cells. ICAM-1 or B7-1 can costimulate naive CD4 T cell activation but both are required for optimum response, J Immunol, 155, 45, 10.4049/jimmunol.155.1.45 Deeths, 1999, ICAM-1 and B7-1 provide similar but distinct costimulation for CD8+ T cells, while CD4+ T cells are poorly costimulated by ICAM-1, Eur J Immunol, 29, 45, 10.1002/(SICI)1521-4141(199901)29:01<45::AID-IMMU45>3.0.CO;2-I Hodge, 1999, A triad of costimulatory molecules synergize to amplify T-cell activation, Cancer Res, 59, 5800 Hodge, 2000, Enhanced activation of T cells by dendritic cells engineered to hyperexpress a triad of costimulatory molecules, J Natl Cancer Inst, 92, 1228, 10.1093/jnci/92.15.1228 Kaufman, 2001, A phase I trial of intralesional rV-Tricom vaccine in the treatment of malignant melanoma, Hum Gene Ther, 12, 1459, 10.1089/104303401750298616 Phan, 2003, Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma, Proc Natl Acad Sci USA, 100, 8372, 10.1073/pnas.1533209100 Steinman, 1973, Identification of a novel cell type in peripheral lymphoid organs of mice. I. Morphology, quantitation, tissue distribution, J Exp Med, 137, 1142, 10.1084/jem.137.5.1142 Freudenthal, 1990, The distinct surface of human blood dendritic cells, as observed after an improved isolation method, Proc Natl Acad Sci USA, 87, 7698, 10.1073/pnas.87.19.7698 Caux, 1996, CD347plus; hematopoietic progenitors from human cord blood differentiate along two independent dendritic cell pathways in response to GM-CSF7plus;TNF alpha, J Exp Med, 184, 695, 10.1084/jem.184.2.695 Banchereau, 1998, Dendritic cells and the control of immunity, Nature, 392, 245, 10.1038/32588 Steinman, 2003, Dendritic cell function in vivo during the steady state, Ann NY Acad Sci, 987, 15, 10.1111/j.1749-6632.2003.tb06029.x Caux, 1992, GM-CSF and TNF-alpha cooperate in the generation of dendritic Langerhans cells, Nature, 360, 258, 10.1038/360258a0 Gabrilovich, 2002, Dendritic cell vaccines for cancer treatment, Curr Opin Mol Ther, 4, 452 Nestle, 1998, Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells, Nat Med, 4, 328, 10.1038/nm0398-328 Mackensen, 2000, Phase I study in melanoma patients of a vaccine with peptide-pulsed dendritic cells generated in vitro from CD34(+) hematopoietic progenitor cells, Int J Cancer, 86, 385, 10.1002/(SICI)1097-0215(20000501)86:3<385::AID-IJC13>3.0.CO;2-T Thurner, 1999, Vaccination with mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma, J Exp Med, 190, 1669, 10.1084/jem.190.11.1669 Zhang, 2002, Advances in dendritic cell-based vaccine of cancer, Cancer Biother Radiopharm, 17, 601, 10.1089/108497802320970217 Berd, 1991, Immunization with haptenized, autologous tumor cells induces inflammation of human melanoma metastases, Cancer Res, 51, 2731 Dranoff, 1995, Gene transfer as cancer therapy, Adv Immunol, 58, 417, 10.1016/S0065-2776(08)60624-0 Soiffer, 1998, Vaccination with irradiated autologous melanoma cells engineered to secrete human granulocyte-macrophage colony-stimulating factor generates potent antitumor immunity in patients with metastatic melanoma, Proc Natl Acad Sci USA, 95, 13141, 10.1073/pnas.95.22.13141 Trefzer, 2000, Hybrid cell vaccination for cancer immune therapy, Int J Cancer, 85, 618, 10.1002/(SICI)1097-0215(20000301)85:5<618::AID-IJC4>3.0.CO;2-Z Morton, 1992, Prolongation of survival in metastatic melanoma after active specific immunotherapy with a new polyvalent melanoma vaccine, Ann Surg, 216, 463, 10.1097/00000658-199210000-00010 Hsueh, 1998, Correlation of specific immune responses with survival in melanoma patients with distant metastases receiving polyvalent melanoma cell vaccine, J Clin Oncol, 16, 2913, 10.1200/JCO.1998.16.9.2913 Sosman, 2002, Adjuvant immunotherapy of resected, intermediate-thickness, node-negative melanoma with an allogeneic tumor vaccine, J Clin Oncol, 20, 2067, 10.1200/JCO.2002.08.072 Rosenberg, 1994, Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2, J Natl Cancer Inst, 86, 1159, 10.1093/jnci/86.15.1159 Dudley, 2001, Adoptive transfer of cloned melanoma-reactive T lymphocytes for the treatment of patients with metastatic melanoma, J Immunother, 24, 363, 10.1097/00002371-200107000-00012 Dudley, 2002, A phase I study of nonmyeloablative chemotherapy and adoptive transfer of autologous tumor antigen-specific T lymphocytes in patients with metastatic melanoma, J Immunother, 25, 243, 10.1097/00002371-200205000-00007 Yee, 2002, Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma, Proc Natl Acad Sci USA, 99, 16168, 10.1073/pnas.242600099 Dudley, 2002, Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes, Science, 298, 850, 10.1126/science.1076514